Genmab is building a deep pipeline of fully human antibody products to maximize its opportunities for success. We have ten products in clinical trials and have the financial flexibility needed to move our products forward. Genmab has chosen to focus on products to treat various cancers, infectious diseases, and autoimmune and inflammatory conditions. Human antibodies are expected to be particularly useful in treating these conditions as they should lend themselves to long-term therapy without the risk of rejection by the body's immune system. Furthermore, Genmab is evaluating a large number of interesting disease targets, including several concerning infectious diseases, for future product development.